Showing results (1-10 of 345) with videos related to
Sort By:
Pageof 35
Expert Opinion on Investigational Drugs|July 1, 2020
Enhancing venetoclax activity in hematological malignanciesToshihisa Satta, Steven GrantClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2023
Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist VenetoclaxToshihisa Satta, Lin Li, Sri Lakshmi Chalasani, et al.Best Practice & Research. Clinical Haematology|October 9, 2021
Clinical experience of CAR T cells for multiple myelomaGary L Simmons, Toshihisa Satta, Omar Castaneda PuglianiniHematological Oncology|July 5, 2022
Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cellsYun Leng, Xiaoyan Hu, Lin Li, et al.British Journal of Nursing (Mark Allen Publishing)|February 28, 2019
Limitations of track and trigger systems and the National Early Warning Score. Part 3: cultural and behavioural factorsSteven GrantLeukemia & Lymphoma|August 26, 2017
Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignanciesSteven GrantBritish Journal of Nursing (Mark Allen Publishing)|June 13, 2018
Limitations of track and trigger systems and the National Early Warning Score. Part 1: areas of contentionSteven GrantThe Journal of Clinical Investigation|August 14, 2012
FAM83A and FAM83B: candidate oncogenes and TKI resistance mediatorsSteven GrantBest Practice & Research. Clinical Haematology|December 5, 2009
New agents for AML and MDSSteven GrantThe Journal of Clinical Investigation|August 30, 2008
Cotargeting survival signaling pathways in cancerSteven GrantPageof 35